ALLR

- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP ® companion diagnostic into 2042 - AACR 2026 data linked higher stenoparib DRP ® scores with enhanced overall survival in advanced ovarian cancer, further supporting DRP ® -guided patient selection - Obtained CLIA certification for its in-house laboratory, enabling full control of DRP ® testing to accelerate and support U.S. clinical trials TARPON SPRINGS, Fla., AUGUST 14, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2026.

Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials must be performed in a CLIA-certified laboratory environment CLIA certification for the Allarity Therapeutics Medical Laboratory is a critical strategic initiative to streamline the development of Allarity's lead agent, stenoparib Positions Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified partner for European companies pursuing U.S. clinical trials or commercialization TARPON SPRINGS, Fla., July 7, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has obtained a Certificate of Registration under the Clinical Laboratory Improvement Amendments (CLIA) for its in-house laboratory.

Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.

Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the United States Patent and Trademark Office (USPTO) has granted the key U.S. patent covering its proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic.

Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript

Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.

Principal Investigator Kathleen N. Moore, M.D.

Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer - Allarity has received a Notice of Allowance for new intellectual property covering its stenoparib-specific DRP ® companion diagnostic - Strong financial position maintained with approximately $29.8 million in cash and restricted cash as of March 31, 2026